Numis Securities Ltd reaffirmed their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a research report released on Monday morning. The brokerage currently has a GBX 37 ($0.46) target price on the stock.
A number of other analysts have also recently commented on AGY. Panmure Gordon reiterated a buy rating and issued a GBX 53 ($0.66) target price on shares of Allergy Therapeutics plc in a research note on Monday, September 26th. Stifel Nicolaus reiterated a buy rating and issued a GBX 72 ($0.89) target price on shares of Allergy Therapeutics plc in a research note on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 22.50 on Monday. Allergy Therapeutics plc has a 52 week low of GBX 17.25 and a 52 week high of GBX 34.82. The stock has a 50 day moving average of GBX 19.09 and a 200-day moving average of GBX 22.01. The stock’s market capitalization is GBX 132.56 million.
In other Allergy Therapeutics plc news, insider Peter Jensen acquired 30,000 shares of the firm’s stock in a transaction on Thursday, September 29th. The stock was acquired at an average cost of GBX 19 ($0.24) per share, for a total transaction of £5,700 ($7,054.46). Also, insider Nicolas Wykeman acquired 150,000 shares of the firm’s stock in a transaction on Tuesday, September 27th. The shares were acquired at an average price of GBX 18 ($0.22) per share, with a total value of £27,000 ($33,415.84).
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.